Patents Assigned to The United States of America as represented by the United States Department of Health and Human Services
  • Pneumococcal fimbrial protein A
    Patent number: 5422427
    Abstract: The present invention relates, in general, to pneumococcal fimbrial protein A. In particular, the present invention relates to a DNA segment encoding a pneumococcal fimbrial protein A gene; polypeptides encoded by said DNA segment; recombinant DNA molecules containing the DNA segment; cells containing the recombinant DNA molecule; a method of producing a pneumococcal fimbrial protein A polypeptide; antibodies specific to pneumococcal fimbrial protein A; and a method of measuring the amount of pneumococcal fimbrial protein A in a sample.
    Type: Grant
    Filed: September 17, 1991
    Date of Patent: June 6, 1995
    Assignee: The United States of America as represented by the United States Department of Health and Human Services
    Inventors: Harold Russell, Jacquelyn Sampson, Steven P. O'Connor
  • 1,2-dihydroellipticines with activity against CNS specific cancer cell lines
    Patent number: 5272146
    Abstract: Certain new 1,2-dihydroellipticine compounds having activity against CNS specific cancer cell lines because of their ease of passage across the blood-brain barrier are disclosed along with formulations and methods for treating CNS cancers employing these compounds.
    Type: Grant
    Filed: October 2, 1992
    Date of Patent: December 21, 1993
    Assignees: The United States of America as represented by the United States Department of Health and Human Services, Purdue Research Foundation
    Inventors: Rudiger D. Haugwitz, Venkatachala L. Narayanan, Mark Cushman, Jurjus Jurayj
  • Human immunodeficiency virus specific proteolytic enzyme and a method for its synthesis and renaturation
    Patent number: 5252477
    Abstract: HIV protease necessary for the natural synthesis of HIV has been identified and sequenced. Rabbit antiserum against the C-terminal portion of HIV protease has been produced and used to isolate natural HIV protease and characterize its activity. In addition, a method for producing synthetic HIV protease having the correct stereospecific conformation and specific HIV proteolytic activity has been achieved.
    Type: Grant
    Filed: June 1, 1987
    Date of Patent: October 12, 1993
    Assignee: The United States of America as represented by the United States Department of Health and Human Services
    Inventors: Stephen Oroszlan, Terry D. Copeland
  • Evaluative means for detecting inflammatory reactivity
    Patent number: 5209920
    Abstract: Inbred Lewis (LEW/N) female rats develop an arthritis in response to Group A streptococcal cell wall peptidoglycanpolysaccharide (SCW) which mimics human rheumatoid arthritis. Histocompatible Fischer (F344/N) rats, on the other hand, do not develop arthritis in response to the same SCW stimulus. To evaluate this difference in inflammatory reactivity between the two strains, the function of the hypothalamic-pituitary-adrenal axis and its ability to modulate the development of the inflammatory response was studied. It has been found that, in contrast to F344/N rats, LEW/N rats had markedly impaired plasma ACTH and corticosterone responses to SCW, recombinant human Interleukin-1 alpha (IL-1 alpha), the serotonin agonist, quipazine, and synthetic rat corticotropin-releasing hormone (CRH). In addition, LEW/N rats compared to F344/N rats had smaller adrenal glands and larger thymuses. Treatment of LEW/N rats with replacement doses of dexamethasone decreased the severity of their SCW-induced arthritis.
    Type: Grant
    Filed: September 25, 1989
    Date of Patent: May 11, 1993
    Assignee: The United States of America as represented by the United States Department of Health and Human Services
    Inventors: Esther M. Sternberg, Ronald L. Wilder, Philip W. Gold, George P. Chrousos